On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

The FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.

The recent FDA approval for GSK's Nucala in COPD treatment and the positive recommendation for Blenrep could significantly enhance the company's revenue and earnings forecasts by expanding its ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

DREAMM-8 is the second phase 3 trial that GSK has been running to potentially mount a case to bring Blenrep back to the market. In late 2022, the company pulled the BCMA-targeted ADC off the U.S ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong ...

In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and ...

GSK itself has suggested it can drive £20bn of additional revenues, Concluding Thoughts - A Solid Quarter Of Growth & A Solidifying Outlook - May Even Offer Some Share Price Upside ...

GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.

For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR (Compound Annual Growth Rate) basis and adjusted operating profit to increase more than 11%, on the same basis.

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...